Author

Karen Lasch 1

1 Takeda Pharmaceuticals USA Inc,Deerfield,United States

Clinical decision support tool predicts risk of infection in patients with inflammatory bowel disease treated with vedolizumab

Parambir Dulai, Ding Feng, Karen Lasch

EFFICACY OF VEDOLIZUMAB WITH AND WITHOUT CONTINUED IMMUNOSUPPRESSANT USE IN GEMINI 1 AND GEMINI 2

Brian G. Feagan, Corey A Siegel, Gil Y. Melmed, Kim Isaacs, Karen Lasch, Maria Rosario, Alexandra Green, Brihad Abhyankar

PATTERNS OF DOSE ESCALATION AMONGST PATIENTS WITH ULCERATIVE COLITIS AND CROHN?S DISEASE TREATED WITH VEDOLIZUMAB VS. INFLIXIMAB IN THE UNITED STATES (US)

Mireia Raluy Callado, Qian Li, Michelle Luo, Karen Lasch, Javaria Mona Khalid

VEDOLIZUMAB DEMONSTRATES EARLY SYMPTOMATIC IMPROVEMENT IN ULCERATIVE COLITIS: A GEMINI 1 POST HOC ANALYSIS

Brian G. Feagan, Karen Lasch, Javaria Mona Khalid, Charlie Cao, Abigail M Wojtowicz, Alexandra James, Jean-Frederic Colombel

Item 1 - 4 / 4
1